Redeye comments on Medivir's Q1 report 2026. The phase II study of fostrox is set up to start with the first patient expected any time now. The cash position of cSEK150m will fund the company through 2026-2027 and the full readout of this study. We make limited changes to our valuation.
LÄS MER
